Drugs / EO-3021
last change Jun 2025 re-read 2 minutes ago

EO-3021

Other / unclassified

Developed for
gastric neoplasm
Investigated by
CSPC Pharmaceutical Group Limited · Elevation Oncology · Eli Lilly and Company · GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05980416 Aug 2023 → May 2025 gastric neoplasm Elevation Oncology Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EO-3021 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05980416
Modality Other / unclassified “Anti-Claudin 18.2 antibody drug conjugate” NCT05980416